B.R.A.I.N. Biotechnology Research and Information Network AG (DE:BNN)
XETRA:BNN
Top Page
B.R.A.I.N. Biotechnology Research and Information Network
(XETRA:BNN)
Select Model
Select Model
Rating:46Neutral
Price Target:
€2.50
▲(5.04% Upside)
Action:UpgradedDate:02/27/26
The score is primarily held down by weak financial performance—persistent losses, consistent cash burn, declining revenue, and a notably weakened 2025 balance sheet with higher leverage. Technical indicators provide a modest offset with price trading above key moving averages and neutral-to-positive momentum, while valuation remains unattractive/limited due to negative earnings and no dividend data.
Positive Factors
Gross margin improvement
An improved gross margin in 2025 indicates the business has regained some product-level economics via pricing, mix or cost control. Over the next 2–6 months sustained improvement could provide operating leverage potential, making progress toward scalable profitability if maintained.
Negative Factors
Persistent unprofitability
Ongoing net losses are a structural weakness that erodes equity and restricts reinvestment. Persistent unprofitability increases reliance on capital markets, raises dilution risk, and undermines long-term return prospects unless operating margins materially improve and losses narrow sustainably.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross margin improvement
An improved gross margin in 2025 indicates the business has regained some product-level economics via pricing, mix or cost control. Over the next 2–6 months sustained improvement could provide operating leverage potential, making progress toward scalable profitability if maintained.
Read all positive factors
B.R.A.I.N. Biotechnology Research and Information Network (BNN) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€52.00M
Dividend YieldN/A
Average Volume (3M)10.93K
Price to Earnings (P/E)―
Beta (1Y)0.31
Revenue Growth-4.90%
EPS Growth-69.80%
CountryDE
Employees296
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding21,847,494
10 Day Avg. Volume22,707
30 Day Avg. Volume10,926
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)25.87
Price to Sales (P/S)0.96
P/FCF Ratio-4.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.00Price Target Upside110.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.31
Revenue Forecast (FY)€55.49M
B.R.A.I.N. Biotechnology Research and Information Network Business Overview & Revenue Model
Company Description
BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical industries in Germany, the United States, France, the Netherlands, and the United Kingdom. The compan...
How the Company Makes Money
BNN generates revenue through multiple streams, including consultancy fees for research services provided to academic institutions and corporate clients, subscription fees for access to its proprietary databases and research findings, and licensin...
B.R.A.I.N. Biotechnology Research and Information Network Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
12
Very Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 49.62M | 54.63M | 55.34M | 49.51M | 38.39M |
| Gross Profit | 2.01M | 401.00K | 3.47M | 1.43M | -1.95M |
| EBITDA | -4.17M | -4.23M | -1.98M | -1.30M | 2.01M |
| Net Income | -11.74M | -11.13M | -8.28M | -6.59M | -4.97M |
Balance Sheet | |||||
| Total Assets | 66.34M | 88.74M | 70.94M | 77.99M | 77.74M |
| Cash, Cash Equivalents and Short-Term Investments | 6.32M | 27.29M | 5.41M | 8.53M | 24.65M |
| Total Debt | 24.03M | 29.82M | 25.32M | 10.74M | 2.64M |
| Total Liabilities | 64.50M | 74.85M | 47.92M | 43.74M | 35.91M |
| Stockholders Equity | 1.84M | 12.62M | 21.77M | 29.64M | 38.78M |
Cash Flow | |||||
| Free Cash Flow | -10.76M | -5.31M | -6.86M | -7.57M | -5.17M |
| Operating Cash Flow | -9.23M | -3.58M | -4.22M | -1.49M | -3.91M |
| Investing Cash Flow | -1.56M | -1.69M | 562.00K | -12.69M | -2.18M |
| Financing Cash Flow | -10.14M | 26.99M | 459.00K | -1.97M | 11.57M |
B.R.A.I.N. Biotechnology Research and Information Network Technical Analysis
Negative
2.38
Price Trends
2.37
Positive
2.57
Negative
2.34
Positive
Market Momentum
0.02
Positive
46.95
Neutral
50.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BNN, the sentiment is Negative. The current price of 2.38 is below the 20-day moving average (MA) of 2.47, above the 50-day MA of 2.37, and above the 200-day MA of 2.34, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 46.95 is Neutral, neither overbought nor oversold. The STOCH value of 50.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:BNN.
B.R.A.I.N. Biotechnology Research and Information Network Peers Comparison
UnderperformOutperform
Sector (55)
DE:BNN
B.R.A.I.N. Biotechnology Research and Information Network
2.38
0.04
1.71%
DE:B8FK
Biofrontera
2.55
0.15
6.03%
DE:GME
Geratherm Medical
2.80
-0.36
-11.45%
DE:HPHA
Heidelberg Pharma AG
3.02
0.26
9.42%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.